(Total Views: 232)
Posted On: 04/09/2019 3:23:17 PM
Post# of 13
$NBIO
Nascent Biotech Moves Corporate Offices to San DiegoPress Release | 04/09/2019
San Diego, CA, April 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) has moved their corporate offices to San Diego, CA.
Nascent CEO Sean Carrick stated, “This is a strategic as well as a fiscal management move that puts our corporate offices close to our R&D Laboratory, as well where we will be performing our Phase I Human Clinical trial for brain cancer. The move will also place our Headquarters in a major biotech center in the United States, placing the company in a more beneficial position to capitalize on expertise and resources of the location in the further development and clinical trials of our antibody.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials in brain cancer. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Nascent Biotech Moves Corporate Offices to San DiegoPress Release | 04/09/2019
San Diego, CA, April 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) has moved their corporate offices to San Diego, CA.
Nascent CEO Sean Carrick stated, “This is a strategic as well as a fiscal management move that puts our corporate offices close to our R&D Laboratory, as well where we will be performing our Phase I Human Clinical trial for brain cancer. The move will also place our Headquarters in a major biotech center in the United States, placing the company in a more beneficial position to capitalize on expertise and resources of the location in the further development and clinical trials of our antibody.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials in brain cancer. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
(0)
(0)
